Clinical benefits of stabilisation with second line chemotherapy in patients with metastatic colorectal cancer

Critical Reviews in Oncology/Hematology

Volumn 32, Issue 2, 1999, Pages 145-154

  Henry, Bernadette ^a   Becouarn, Yves ^b   Aussage, Pierre ^a  

^a Anal et Rech en Econ de la S   (France)

^b INSTITUT BERGONIÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; COLORECTAL CANCER; FEMALE; HEALTH STATUS; HOSPITAL COST; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; QUALITY OF LIFE;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; FRANCE; HOSPITAL COSTS; HUMANS; LENGTH OF STAY; NEOPLASM METASTASIS; PALLIATIVE CARE; PATIENT ADMISSION; PROSPECTIVE STUDIES; QUALITY OF LIFE; SICKNESS IMPACT PROFILE;

EID: 0032745373     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(99)00044-X     Document Type: Article

References (26)

1. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J. Clin. Oncol. 10:1992;896-903.
2. Cunningham D., Findlay M. The chemotherapy of colon cancer can no longer be ignored. Eur. J. Cancer. 29A:1993;2077-2079.
3. Hilgenfeld R.U., Streit M., Theil E. et al. Current treatment modalities in advanced colorectal carcinoma. Rec. Results Cancer Res. 142:1996;353-380.
4. Bécouarn Y, Brunet R, Ravaud A. et al. Chimiothérapie systémique des adénocarcinomes colorectaux métastatiques. Gastroenterol Clin Biol 1992; 16: 166-176.
5. Rougier P., Bugat R., Douillard J.Y. et al. Phase II study of Irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients treated with Fluorouracil-based chemotherapy. J. Clin. Oncol. 15:1997;251-260.
6. Wiseman L.R., Markham A. Irinotecan: a review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs. 52:1996;606-623.
7. Rougier P., Van Cutsem E., Bajetta E. et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 352(9138):1998;1407-1412.
8. Blijham G., Mesbah M., Glimelius B. Quality of life (QOL) evaluation of CPT-11 compared to best supportive care (BSC) or infusional 5FU in patients (PTS) with 5FU-resistant advanced colorectal cancer (ACRC) [abstract 1592]. The American Society of Clinical Oncology, 34th Annual Meeting, May 16-19, 1998. Proceedings of ASCO. 17:1998;413a.
9. Cunningham D., Pyrhönen S., James R.D. et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 352(9138):1998;1413-1418.
10. Machover D., Diaz-Rubio R., de Gramont A. et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann. Oncol. 7:1996;95-98.
11. Bleiberg H., de Gramont A. Oxaliplatine plus 5-Fluorouracil: clinical experience in patients with advanced colorectal cancer. Semin. in Oncol. 25(2, suppl. 5):1998;32-39.
12. Schmoll HJ. Is there a second line therapy in colorectal cancer? ESMO Educational book. 1996, p. 35-42.
13. Miller A.B., Hoogstraten B., Staquet M. Reporting results of cancer treatment. Cancer. 47:1981;207-214.
14. Van Cutsem E., Rougier P., Droz J.P. et al. Clinical benefits of Irinotecan (CPT-11) in metastatic colorectal (CRC) resistant to 5-FU. Proc. Am. Soc. Clin. Oncol. 16:1997;268a. [abstract 950].
15. Launois R., Reboul-Marty J., Henry B. et al. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Pharmacoeconomics. 10(5):1996;504-521.
16. Feeny D., Furlong W., Boyle M. et al. Multi-attribute health status classification systems: health utilities index. Pharmacoeconomics. 7(6):1995;490-502.
17. Feeny D., Furlong W., Barr R.D. et al. A comprehensive multi-attribute system for classifying the health status of survivors of childhood cancer. J. Clin. Oncol. 10(6):1992;923-928.
18. Echelle nationale des coûts par Groupes Homogènes de Malades. Ministère des Affaires Sociales. Bulletin Officiel N°96/7 bis, 1996.
19. Schwartz D, Méthodes statistiques à l'usage des médecins et des biologistes. Coll. Statistique en Biologie et en Médecine. Ed. Flammarion Médecine-Sciences. 3rd ed. 1969.
20. Expectancy of primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J. Clin. Oncol. 10:1992;904-911.
21. Scheithauer W., Rosen H., Kornek G.V. et al. Randomised comparison of combination chemotherapy plus supportive care alone in patients with metastatic colorectal cancer. Br. Med. J. 306:1993;752-755.
22. Glimelius B, Hoffman K, Graf W et al. for the Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. Cancer 1994;73:556-562.
23. Van Cutsem E., Cunningham D., Ten Bokkel Huinink W.W. et al. Clinical activity and benefit of irinotecan with colorectal cancer truly resistant to 5-fluorouracil (5-FU). Eur. J. Cancer. 35(1):1999;54-59.
24. Petrou S., Campbell N. Stabilisation in colorectal cancer. Int. J. Palliat. Nurs. 3(5):1997;275-280.
25. Utilities: rating scale, time trade-off, and standard gamble techniques. Spilker B. Quality of Life and Pharmacoeconomics in Clinical Trials. second edition:1996;Lippincott Raven.
26. Blijham G., Schmitt C., Aussage P. et al. Cost-effectiveness of Irinotecan (CPT-11) and best estimated chemotherapy regimen in patients with metastatic colorectal cancer after failure of 5 fluorouracil (5-FU) containing regimen: results based on a phase III trial. The First European Conference on the Economics of Cancer, Brussels, November 19-21, 1997. Eur. J. Cancer. 33(suppl. 9):1997;S2. Abstract.